For Immediate Release - November 11, 2003

Under the terms of the agreement, Aloka will manufacture for Hologic, under a joint label, a high performance, fully functional diagnostic ultrasound system optimized for women's imaging, with emphasis on finding and diagnosing abnormalities within the breast. Hologic's exclusive distribution rights extend to radiology-based sales where breast-imaging systems are highly utilized, and, in addition to the ultrasound system, include compatible optional components and future technological enhancements and upgrades. The system has been designed to incorporate Aloka's proprietary ProSound package of technologically advanced features including; Digital Pure Beam imaging, Tissue Harmonic Echo technologies, 3-D Color Doppler capabilities, a 12-bit AD converter to enable higher contrast resolution, and an integrated DICOM compatible image management solution.

According to Jack Cumming, Hologic's Chairman and CEO, "This is a very important and exciting agreement for Hologic. It brings Hologic a step closer to fulfilling our commitment to provide a comprehensive portfolio of the highest quality diagnostic breast imaging products available, to assist in earlier detection of breast cancer.

"Our selection of Aloka was based on a thorough evaluation of available ultrasound technologies," continued Cumming. "Our system specifications focused on the highest image quality, a versatile feature-set, simplicity of use for technologists and physicians, and affordable pricing for women's imaging suites that are suffering from overall reimbursement pressures. We believe the system we have customized with Aloka for breast imaging is an elegant system that eclipses all of our selection criteria. In addition and most importantly, Aloka shares our passion for improving healthcare for women. We look forward to a long and productive working relationship."

Hologic's product offerings include the Lorad SeleniaT, the industry's only full field digital mammography system using direct capture technology and the M-IV and Affinity Series of screen-film mammography systems. The company also provides both upright and prone stereotactic breast biopsy systems. In addition, a recent distribution agreement with R2 Technology allows the company to offer a range of Computer Aided Detection (CAD) product offerings to be utilized with their mammography systems.

"Aloka's superior ultrasound imaging complements Hologic's high performance mammography systems and is a natural good fit in Hologic's product line, " according to Lee Oppegaard, Vice President of Marketing and Business Development for Aloka.

David Famiglietti, Aloka's COO, remarked, "Hologic's proven track record of delivering excellent product solutions combined with a focus on customer support parallels our customer centric approach at Aloka. This relationship will not only be good for both companies, but for customers and patients as well."

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the relationship and anticipated benefits from Hologic's agreement with Aloka Company Ltd. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, Hologic's and Aloka's limited experience in working together; Hologic's substantial dependence on the efforts of Aloka to make this relationship successful; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, such as the ability to obtain FDA approval to market products developed, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for digital x-ray products; risks relating to Hologic's reliance on a single source of supply for some key components of its products; the need to comply with especially high standards in the manufacture of digital x-ray products; Hologic's ongoing ability to satisfy financial and other covenants in its credit and lease agreements; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.